Management of three-dimensional intrafraction motion through real-time DMLC tracking

Management of three-dimensional intrafraction motion through real-time DMLC tracking.

Tumor tracking using a dynamic multileaf collimator (DMLC) represents a promising approach for intrafraction motion management in thoracic and abdominal cancer radiotherapy. In this work, we develop, empirically demonstrate, and characterize a novel 3D tracking algorithm for real-time, conformal, intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT)-based radiation...

Real-Time Intrafraction Motion Management During Radiotherapy

Real-time intra-fraction target tracking is a technique that enables adjustment of the target radiation while it is being delivered (i.e., intra-fraction adjustments) to compensate for movement of the organ inside the body. Real-time tracking, which may or may not use radiographic images, is one of many techniques referred to as “image-guided radiotherapy” (IGRT). For this policy, realtime trac...

Real-Time Intrafraction Motion Management During Radiotherapy

Four-dimensional radiotherapy planning for DMLC-based respiratory motion tracking.

Four-dimensional (4D) radiotherapy is the explicit inclusion of the temporal changes in anatomy during the imaging, planning, and delivery of radiotherapy. Temporal anatomic changes can occur for many reasons, though the focus of the current investigation is respiration motion for lung tumors. The aim of this study was to develop 4D radiotherapy treatment-planning methodology for DMLC-based res...

The non-Gaussian nature of prostate motion based on real-time intrafraction tracking.

PURPOSE The objective of this work is to test the validity of the Gaussian approximation for prostate motion through characterization of its spatial distribution. METHODS AND MATERIALS Real-time intrafraction prostate motion was observed using Calypso 4-dimensional (4D) nonradioactive electromagnetic tracking system. We report the results from a total of 1024 fractions from 31 prostate cancer...